Good afternoon, and welcome to the Omnicell fourth quarter and full year 2022 financial results conference call. On the call with me today are Randall Lipps, Omnicell Chairman, President, CEO, and Founder, Scott Seidelmann, Executive Vice President and Chief Commercial Officer, and Peter Kuipers, Executive Vice President and Chief Financial Officer. This call will contain forward-looking statements, including statements related to financial projections or other statements regarding Omnicell's plans, objectives, expectations, cost-saving actions, or outlook that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. For a more detailed description of the risks that impact these forward-looking statements, please refer to the information in our press release issued today in the Omnicell Annual Report on Form 10-K filed with the SEC on February 25th, 2022, and in other more recent reports filed with the SEC. Please be aware that you should not place undue reliance on any forward-looking statements made today. All forward-looking statements speak only as of the date hereof or the date specified on the call. Except as required by law, we do not assume any obligation to update or otherwise release publicly any revisions to our forward-looking statements. Our results were released this afternoon and are posted in the Investor Relations section of our website at ir.omnicell.com. We would like to remind you that during this call, we will discuss some non-GAAP financial measures. Reconciliation of these non-GAAP measures to the most comparable GAAP financial measures are included in our financial results press release issued today. With respect to forward-looking non-GAAP measures, we did not provide a reconciliation of forward non-GAAP measures to the comparable GAAP measures on a forward-looking basis as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. With that, I will turn the call over to Randall. Randall. Good afternoon, and thank you for joining us today. I'd like to begin by providing some context on what we are currently seeing as it relates to the overall healthcare environment and the medication management markets that we address. We'll also discuss the Form 8-K we filed today detailing additional cost savings actions we are taking in an effort to ensure we are well-positioned to navigate the ongoing economic challenges we face. I then will walk through some highlights for the fourth quarter and full year 2022, as well as our priorities for 2023. Starting with the current healthcare environment. Capital committees within our health system partners continue to look to be highly focused on ensuring optimal ROI for their budgetary spend and investments. We believe we are in a strong position to help our health system and retail customers realize savings and ROI as they invest in Omnicell's connected devices and SaaS and tech-enabled services. Although it appears most customers are still in a capital-constrained environment, we believe we are uniquely positioned to help health systems address many of the medication management pain points they are facing today. While we are pleased to see greater stability within our customer base, we remain mindful of the potential ongoing headwinds given the continued macroeconomic uncertainty for us and our customers. As a result, we intend to take what we believe is a cautious stance on how we manage the business. In November 2022, we disclosed that we were reducing our workforce by approximately 9% across a majority of our functions. We are continuing to refine our cost structure and are maintaining a focus on expense management to align with our anticipated revenues. In view of that, today we announced we will be further reducing our workforce across many of our functions. In addition, we are reducing our real estate footprint to align with our broader hybrid work strategy and to further reduce costs. To that end, we expect to reduce square footage by the end of the second quarter of 2023. Through these initiatives, including the reduction in workforce we announced in November 2022, along with other expense containment efforts, we anticipate the annualized savings from operating expenses to be around $50 million for 2023, which does not include the expected volume-based reductions within cost of sales. While it is always difficult to make decisions that adversely impact our employees, we are not immune to the challenges companies across many industries continue to face, we are committed to taking actions we believe will help us to be well-positioned for the long term. Turning to some of the highlights of the fourth quarter and full year 2022. As I meet with our customers, several things are becoming increasingly clear to me. First, Omnicell's advanced services provide measurable ROI. We believe this is important to our healthcare partners, particularly in the current economic environment. In addition, our connected devices and advanced services improve compliance, and we believe also improve nurses' and pharmacists' day-to-day work experience. This in turn appears to be improving patient care. We believe this combination of factors validates our strategy and the industry vision of the Autonomous Pharmacy. The market demand for our service is clear to us. We are energized by our mission and believe we are uniquely positioned to help our health systems and retail partners to transition to a next generation cloud native capabilities that we anticipate will ultimately transform the pharmacy care delivery model. Second, despite what continues to be a challenging macroeconomic environment, customers are continuing to convert from competitors to Omnicell. We announced two new long-term sole source agreements during the 2nd half of 2022, and we added a new competitive conversion during the 4th quarter of 2022. This brings us to sole source contracts with more than half of the top 300 U.S. health systems. We believe these new wins exemplify the customer momentum in our advanced services that continued throughout the end of the year. Scott will speak to our customer wins in more detail momentarily. While we are seeing stabilization among our customers' capital spend with respect to connected devices, we remain confident in our expected growth trajectory of advanced services, particularly our robotic-based services such as IVCS and CPDS. This positive momentum reaffirms our belief and our long-term vision to transform Omnicell to an as a service company. While 2022 presented unprecedented challenges within the industry, we are focused on the long term and believe we are well positioned to deliver increasing value for all our stakeholders. Turning to our high level financial results. 2022 bookings were $1.054 billion compared to $1.217 billion for full year 2021, reflecting a slowdown primarily in our point of care bookings, particularly offset by an increase of an advanced services bookings. Our full year 2022 GAAP revenues were $1.296 billion, and non-GAAP revenues were $1.297 billion, an increase of 14% from the prior year. Full year 2022 GAAP earnings per share were $0.12 per share, and non-GAAP earnings per share were $3 per share. We intend to manage the company to deliver growth and GAAP earnings over the long term. We expect this will require a more targeted approach to our stock-based compensation programs and overall cost efficiency. Now, looking ahead to 2023. As I noted earlier, we intend to take what we believe is a cautious approach to managing the business given the current macroeconomic environment. Our priorities for 2023 are the following. One, deploying what we think is a prudent plan to pursue our growth agenda while also working to lower cost and improve efficiencies throughout the company. Two, continuing to make meaningful progress on the integration of recent acquisitions to drive expected synergies. three, invest in R&D and innovation that is expected to drive future growth. To reiterate, while we face challenges in 2022, my conviction in Omnicell's future has never been stronger. I look forward to working alongside the Omnicell team as we endeavor to deliver long-term value for all of our stakeholders. Before I turn the call over to Scott, I would like to note that we announced today that Peter Kuipers will be stepping down from his role as CFO and will be leaving the company on July first, 2023. I've worked closely with Peter over the last seven years and appreciate the significant contributions Peter has made to Omnicell over that time. Peter joined the company when our revenues were just under $500 million annually, and we just concluded 2022 with nearly $1.3 billion in revenue. Now, we have launched a search for our next CFO, and Peter will help to ensure a smooth transition. Thank you, Peter. With that, I will turn the call over to Scott. Thank you, Randall. As Randall noted, we are encouraged that demand conditions within health systems and hospitals appear to be stabilizing. Our customers continue to face labor constraints in many cases remain under capital budget freezes. While we have seen this environment primarily impact our point of care business, we are continuing to see strong demand for our advanced services. Advanced services are a key part of our intelligent medication management infrastructure, which is intended to help customers address problems in their medication management processes from the inpatient bed to the home. Let's walk through a few of our recent wins that we believe highlight the power of our offering. First is an Ohio-based health system that has chosen to partner with us for Central Pharmacy Dispensing Service, IV Compounding Service, and our Inventory Optimization Service. Additionally, this health system will convert to our XT Automated Dispensing System. We believe that the comprehensive nature of our solution was critical to winning this competitive conversion. In Q4, one of the largest integrated healthcare networks in Tennessee and an existing customer upgraded its ADCs to our XT dispensing system and also contracted for Central Pharmacy Dispensing Service, IV Compounding Service, and our Inventory Optimization Service. The health system has indicated that they partnered with us because of the potential total value creation of our solution across their medication management care delivery model. As part of our advanced services portfolio, our recently acquired Specialty Pharmacy Service continues to gain traction with health systems that are looking for a partner that can help to quickly stand up or optimize their specialty pharmacy operations. For example, in Q4, the largest private teaching hospital in Florida chose to partner with Omnicell to establish a new specialty pharmacy program, citing our specialty pharmacy expertise and managed services model as key reasons for the partnership. Overall, we are very pleased with the demand that we are seeing for our advanced services, and as such, in 2023, we will continue R&D investment across the portfolio. Additionally, for EnlivenHealth in 2023, we will focus on integrating the technology platforms of the 2 companies that we acquired in late 2021. We believe that the strong demand we have seen for our advanced services, coupled with our continued R&D investment, should position us well for growth in the future. With that, I will turn the call over to Peter. Thank you, Scott. Good afternoon. 2022 was a challenging year for the company. We found that many health systems and hospitals reacted to the ongoing macroeconomic challenges by implementing capital budget freezes and additional capital approval requirements, resulting in elongated sales cycles. This mostly impacted our point of care business and resulted in the company lowering its full year 2022 guidance. I'm pleased to note that we have not seen further deterioration in the healthcare environment in the last quarter of 2022 and so far in 2023. For fourth quarter 2022, we delivered results that generally exceeded our revised 2022 guidance ranges. Our healthcare system and retail pharmacy customers look to continue to rely on and partner with Omnicell to help them deliver improvements in patient care, to achieve return on investment, and build long-term strategic relationships in an effort to realize the industry vision of the Autonomous Pharmacy. Our fourth quarter 2022 GAAP and non-GAAP revenues were $298 million, or $3 million above the top end of our revised 2022 guidance range. A full reconciliation of our GAAP to non-GAAP results is included in our fourth quarter and full year 2022 earnings press release and is posted on our investor relations website. Our fourth quarter 2022 earnings per share in accordance with GAAP were a loss of $0.64 per share compared to income of $0.37 per share in the previous quarter and income of $0.28 per share in the fourth quarter of 2021. The fourth quarter 2022 earnings per share in accordance with GAAP includes the impact of $70 million for severance-related expenses as disclosed in the Form 8-K we filed on November 30th, 2022, as well as the impact of $4 million for the impairment of operating lease right of use assets as we rationalized our office space as part of the effort to align with our broader hybrid work strategy. Non-GAAP gross margin for the fourth quarter of 2022 was 45.3%, a decrease of 220 basis points from the previous quarter, primarily due to lower revenue volume average. Cost actions, including the previously announced headcount reductions in November 2022, generally had very little impact on the fourth quarter 2020 results. We expect to begin to see the benefit from these actions on gross margin and operating expenses more fully in the second quarter of 2023. We expect to see volume leverage beginning to return by the fourth quarter of 2023 as revenue is projected to grow throughout the year. Fourth quarter non-GAAP EBITDA was $26 million compared to $61 million in the previous quarter and $52 million in the same period last year. Fourth quarter 2022 non-GAAP earnings per share were $0.33 per share compared to $1 per share in the previous quarter and $0.92 per share in the same period last year. Fourth quarter non-GAAP earnings per share were above our revised fourth quarter 2022 guidance due to higher revenue, lower cost of sales, solid expense management, and lower performance-based compensation. Turning now to review our full year 2022 results. Bookings for full year 2022 were $1,054 million compared to $1,217 million for the full year 2021. Bookings decreased 13% over the prior year, primarily due to a slowdown in point of care bookings as an increasing number of health systems implemented CapEx, budget freezes, or additional CapEx approval requirements, partially offset by an increase in advanced services bookings. Our total backlog was $1.215 billion as of December 31st, 2022, compared to $1.254 billion as of December 31st, 2021. As further detailed on slide 13 of our earnings presentation. In the Form 8-K we filed today and published on our investor relations website prior to today's call, we are now providing additional information about the portion of our backlog derived from both product and advanced services bookings. Backlog represents the dollar amount of bookings for our products and advanced services which have not yet been recognized as revenue. We consider backlog that is expected to be converted to revenues in more than 12 months to be long-term backlog. Product backlog includes connected devices such as our XT Series Automated Dispensing System and the product portion of our Central Pharmacy Dispensing Service and IV Compounding Service. Product backlog as of December 31st, 2022 was $797 million, of which $503 million is short-term product backlog and $294 million is long-term product backlog. We believe a majority of the long-term product backlog will be convertible into revenues between 12 and 24 months. Advanced services backlog only includes the portion of our advanced services multiyear contracts which have a stated minimum commitment within the agreement. Advanced services include services such as our EnlivenHealth solutions, 340B solutions, Specialty Pharmacy Services, Inventory Optimization Service, and other software solutions, as well as the service portion of our Central Pharmacy Dispensing Service and IV Compounding Service. While we partner closely with our customers when providing advanced services, and the majority of our advanced services are provided under multiyear contracts, only a portion of these contracts have stated minimum commitments. Advanced services backlog consisting of minimum contractual commitments as of December 31st, 2022 was $418 million, of which $50 million is short term advanced services backlog and $369 million is long term advanced services backlog. Long-term advanced services backlog typically represents multiyear subscription agreements, usually with contractual terms of between two and seven years, some of which have not yet been implemented, which will be converted to revenue ratably over the contractual term. Despite the challenging macroeconomic environment, our full year 2022 GAAP revenues were a record $1.296 billion, and non-GAAP revenues were a record $1.297 billion. Our 2022 non-GAAP revenues saw an increase of $164 million or 14% from 2021. The strong year-over-year non-GAAP revenue increase reflects continued demand for Omnicell's medication management and adherence automation solutions, as well as the contribution of revenue from scaling advanced services and the impact of recent acquisitions. Our full year 2022 earnings per share in accordance with GAAP were $0.12 per share. Our full year 2022 non-GAAP earnings per share were $3 per share, a decrease of $0.81 per share or 21% from 2021. The year-over-year decrease was mostly driven by reduced operating leverage from lower than originally expected revenue during the second half of 2022. For full year 2022, total inflationary costs were $26 million, which is $4 million lower than expected at the time of the third quarter 2022 earnings call, primarily due to moderation in semiconductor, steel, and freight cost inflation. For full year 2022, we delivered non-GAAP EBITDA of $192 million, which is above our 2022 revised guidance range. Full year 2022 non-GAAP EBITDA margin of 15% was a decrease of 540 basis points from the previous year. Moving to cash flow. Full year 2022 free cash flow of $17 million. A decrease of $156 million is primarily due to lower GAAP net income, as well as the impact of higher inventory and timing of cash collections. At the end of the fourth quarter of 2022, our cash balance was $330 million, up from $266 million as of September 30th, 2022. The $64 million increase in cash is the result of strong free cash flow and record cash collections in the fourth quarter of 2022. Free cash flow during the fourth quarter of 2022 was $65 million compared to $5 million from the previous quarter and $43 million in the fourth quarter of 2021. In terms of accounts receivables, days sales outstanding for the fourth quarter of 2022 was 93 days, unchanged from the previous quarter. Inventories as of December 31st, 2022 were $148 million, an increase of $1 million from the prior quarter and an increase of $28 million from the fourth quarter of 2021. It is important to note that the inventories as of December 31st, 2022 include approximately $18 million of advance purchases and receipts of semiconductors that we believe will help reasonably secure supply for future customer implementation timelines. While supply and demand for semiconductors are becoming more balanced, lead times continue to be long. The teams continue to execute well as we adjust to revised revenue volumes, particularly for point of care. We continue to expect with a high level of confidence that our supply chain has and will continue to procure critical components for our products, including semiconductors, to deliver our mission-critical systems and connected devices to our healthcare customers. Now, moving on to 2023 full year and first quarter 2022 guidance. Given the continued macroeconomic uncertainty, we expect 2022 bookings to be between $1 billion and $1.1 billion. Bookings includes both the bookings from products as well as the bookings from our advanced services. The midpoint of the 2022 bookings guidance is approximately equal to our full year 2022 bookings. For full year 2023, we expect total revenues to be between $1.15 billion and $1.19 billion. We expect product revenue to range between $740 million and $760 million, consisting of expected revenue from short-term product backlog, to a lesser extent, revenue from within year bookings, and from recurring consumables revenue. We expect 2023 service revenues to be between $410 million and $430 million. Our service revenue includes both revenue from advanced services as well as revenue from technical services. We expect service revenue from advanced services revenue to be between $200 million and $210 million, which is a 10% increase at the midpoint compared to 2022, and represents approximately 18% of 2023 revenues. The 2023 advanced services revenue consists of recurring revenue of the installed base of advanced services solutions and the expected revenue from the short-term advanced services backlog, and to a lesser extent, expected new advanced services implementations. We expect service revenue from technical services, which includes our post-installation technical support, training, and customer education solutions, to range between $210 million and $220 million in 2023, an increase of 4% as compared to 2022. Please see slide number 14 in our earnings presentation, published on our investor relations website, for a summary of the revenue guidance components. Today, we also announced a reduction in force as part of our cost containment measures, together with the cost containment actions we announced in November 2022, in an effort to create operating leverage and align our cost with expected revenue volume. Of the total reduction in force announced in November as well as today's announcement, approximately half of the headcount reduction was within functions included in cost of sales, mostly from reduced volume. Of the portion of reduction in force that will reduce operating expenses going forward, nearly all was within functions included in SG&A, with very little in R&D, as we continue to make key investments that are expected to drive innovation. We expect gross margin percentage to modestly expand in the second half of 2023 due to the expected benefits from these cost containment actions, as well as expected volume leverage, increased impact of pricing actions, and moderating inflationary costs. We continue to seek to balance cost containment with investing in innovation, specifically including advanced services and strategic next-generation automation solutions. A majority of the approximately $50 million of anticipated annual operating expense savings expected to be derived from the recent reductions in force and other expense containment efforts is from functions included in SG&A. The expected 2023 operating expense annual savings will be largely offset by the impact of year-over-year inflation in employee salaries and increases in expected performance-based compensation, vendor cost increases, and investments in R&D. We expect non-GAAP operating expenses in total to be slight year-over-year, with non-GAAP SG&A down slightly offset slightly by an increase in non-GAAP R&D, which reflects our focus on cost savings while continuing investments in our growth agenda. We expect total year 2023 non-GAAP EBITDA to be between $120 million and $135 million. The total year 2023 non-GAAP EBITDA guidance includes the impact from estimated lower revenue volume, cost actions designed to create operating leverage, expected reduced inflationary pressures, and anticipated favorable impact from the pricing actions we've put in place in recent years and which we expect to have a greater impact in 2023. We expect EBITDA margins to expand as we move through 2023 based on the projected timing of cost actions, pricing actions, and the impact of volume leverage for the gross margin and operating expenses in the second half of the year. We expect 2023 non-GAAP earnings to be between $1.55 and $1.80 per share. This takes into account a lower expected blended tax rate in 2023 and the expected increase in share count as a result of new shares being issued under our employee stock plans. For full year 2023, we are assuming an effective blended tax rate of approximately 5% in our non-GAAP earnings per share guidance, compared to an actual blended tax rate of 6% in 2022. For the first quarter of 2023, we are providing the following guidance. We expect total first quarter 2023 revenues to be between $273 million and $283 million, with product revenues to be between $179 million and $184 million, and service revenues to be between $94 million and $99 million. We expect first quarter 2023 non-GAAP EBITDA to be between $6 million and $12 million. We expect first quarter 2023 non-GAAP earnings per share to be between $0.04 per share and $0.14 per share. We are seeing strength in our customer partnerships, which include long-term sole source agreements with over 150 of the top 300 U.S. health systems. Of our customers in the top 300 U.S. health systems, more than half have contracted for at least one of our advanced services. As advanced services are scaling, we see strong momentum in the pipeline to continue to expand the adoption of our advanced services within the top 300 U.S. health systems. We continue to strive to deliver value for all of our stakeholders in this challenging macroeconomic environment. We remain confident in our potential long-term opportunities. We look forward to updating you on our progress in the coming quarters. Lastly, I want to thank Randall for your kind words earlier in the call. It has been a great privilege to have worked with you, our executive leadership team, our board of directors, and all of the incredible people who make Omnicell a great company. I'm grateful to have led the finance, global supply chain, international, IT, and corporate development teams, and to have played a part during the time of scaling and business model transformation. I'm proud of being a part of the team that has created such value within healthcare. At this point, I have accomplished the objectives I've set out to achieve when I joined Omnicell over seven years ago, and I'm looking forward to the next chapter in my career. I will be supporting the team as the search for my successor commences, and I will help to assist in a smooth transition later this year. I know that the company is very well positioned to continue to evolve and take full advantage of the need for medication management automation solutions, and I will always wish Omnicell great success. With that, we would like to open the call for your questions. The floor is now open for your questions. To ask a question at this time, please press star one on your telephone keypad. If at any point you'd like to withdraw from the queue, please press star one again. You'll be provided the opportunity for one question and one further follow-up question. We will now take a moment to render our roster. Our first question comes from Stan Berenshteyn from Wells Fargo Securities. Please proceed. Hi. Thanks for taking my questions. I guess first, Peter, it's been a pleasure working with you. Wish you the best of luck. Maybe first, I wanna also say thank you for breaking down the backlog details. That was very helpful. Maybe first, I just wanted to get a clarifying question. The announced savings that you announced today, is that also factored into guidance that you provided for the full year? Yeah. Thank you, Stan. As I said, this is Peter. Really like working with you as well. Yes, to your last question, the impact of the cost actions today, or cost containment actions, are included and factored into the guidance that we provided, both for total year 2023 and also for the first quarter of 2023. Got it. Okay. That's helpful. On advanced services. Comments on advanced services from, I believe last quarter, seemed to suggest that pacing expectations were pretty much unchanged from the Investor Day. It seems like the guidance you've provided right now, the expectations have, you know, somewhat moderated. Is there anything to specifically call out of what changed from maybe a quarter or two ago? Hey, Stan. It's Scott. No, not really. I think that we continue to see strong demand. We continue to be excited. I think that, you know, generally, the advanced services deliver a positive ROI for the customers, and that's why we continue to see demand in this macroeconomic environment. I think as it relates to the guidance in 2023, I think that, you know, obviously we're taking a cautious approach to this. Got it. You know, we'll go from there. Yeah. Maybe to add to that. Really the guide for bookings for 2023, if you click down on that, we're not breaking out or delineate the bookings between core product bookings and advanced services bookings. Within that, core bookings are expected to be down through the year, and advanced services bookings are expected to be increasing very well, if you will, from a delineation perspective. Got it. Maybe one quick one here on the point-of-sale XT products. It seems like you've been upgrading them recently based on them reaching end of life. You should obviously have good visibility there as you think, you know, beyond 2023. I'm just curious, if we think into 2024, maybe even 2025, what's the replacement pipeline looking like in 2024 and 2025? Is it steady versus 2023 higher or lower? Any, any guidance you can give us here? We do have a solid pipeline of replacements over the next handful of years. I think we do look at that as we do have predictability to it. It is steady. It's only a component of ADC sales in any given quarter, so it does give us nice predictability. Thank you. Thanks, Stan. Next question, please. Our next question comes from the line of Matt Hewitt from Craig-Hallum Capital Group. Please proceed. Good afternoon, and I'll echo the other comments on Peter. Congratulations and best of wishes in your future endeavors. Maybe the first one for me, and you talked about this a little bit, but I'm wondering if we could get a little more color on the hospital budgets and capital freezes. It sounds like things were relatively stable Q4 so far into Q1. What are you hearing from customers? How are they prioritizing? Obviously, they still need equipment. They still need to upgrade some pieces, even yours. I'm just curious what you're hearing from them, and what are their expectations as the year progresses? Yeah, this is Randy. I think we're definitely seeing a stabilization in the market and but people are still being pretty cautious on committing capital to more systems until they really have to. You know, when systems do come out of date or they do an expansion, then well they go ahead and put those through. I think it gives us comfort in that we don't see any decrease in the market. We haven't seen any significant uptake yet, but, I think it gives us a good starting point for the year. I think we're still gonna be cautious about the macroeconomic environment because I think it's still unsettling not having a few more quarters of positive results for these health systems. Fair enough. Then maybe a question on the Specialty Pharmacy business, congratulations on the win there. As you look out over the course of this year, it sounds like you're having good discussions. Should we be looking at that as a nice growth driver for you this year and maybe kind of setting the stage for, you know, 2024 and beyond, clearly a nice driver this year? This is Scott. Absolutely. specialty pharmacy and the sort of creation or growth of in-house specialty pharmacies for health systems is certainly a tailwind. The market is trending very positively there. Then, we are very bullish and excited about the growth of our offering there. Great. Thank you. Our next question comes from the line of Scott Schoenhaus from KeyBank. Please proceed. Thanks, guys. Thanks for taking my question. Peter, it's a pleasure knowing and working with you over these past several years as well. I guess my first question is on the margins. Your first quarter implied margins are 3%. We haven't really seen that since 2017, it implies a steep acceleration throughout the rest of the year. Can you kind of walk us through what's embedded in guidance? Is it a, you know, a sequential stair-step that's spread evenly over each quarter, or is there some seasonality with these cost cuts and orders coming in? Can you just help us walk through this steep acceleration from 3% to, you know, high double digits to get to your 10% margins for the year, please? Thanks. Yeah. Thank you. Thank you, Scott. Great working with you as well. Yeah, I think, you know, you mentioned most of the drivers there, right? Really going through the year, the cost actions that we announced both in November and this year, both in cost of sales and in operating expenses, will have a more full impact to the P&L, really starting in the middle of the year. We see the ramp-up there, if you will, from a profitability perspective. Also the second half of the year, we see more volume leverage, specifically as advanced services scale more, and then also we see some improvement in volume leverage in point of care as well. Lastly, we see pricing actions that we announced previously coming through more heavily and impacting every single quarter as we go through the year. Lastly, the inflationary cost for semis, steel, and freight, we expect to further moderate in 23 in quarters. For this year, we actually see pricing actions exceeding the inflationary costs for those three components. Great. I guess as my follow-up, how are you thinking about capital allocation, from this point forward? Thanks, guys. Yeah. I would say from a capital allocation perspective, I think Randall mentioned earlier the approach for the year as far as the planning and the guide. Fair to say that M&A strategic acquisition is probably a little bit lower on the priority from that perspective. We want to make sure we got a large cash balance as we enter the year, of course, as well. Our next question comes from the line of Jessica Tassan from Piper Sandler. Please proceed. Hi, thank you guys so much for the questions. Peter, thanks for all the help over the last couple of years. I'm sure we'll be in touch between now and July. Sorry to see you go. I guess maybe for my first one, is there a difference between recurring or subscription advanced services revenue and what is appearing in short-term backlog for advanced services? Thank you for the question. The, well, subscription is part of recurring, right? That's the way to see it. It's almost similar for advanced services. For your second question, in the prepared remarks, and then also in the investor deck that we posted, advanced services backlog solely or exclusively is only the minimum contractual commitments in the advanced services multi-year contracts. It does not include the run rate offered of the installed base that are not covered by minimum commitment contracts. Got it. Advanced services bookings would include the run rate, and then backlog only includes the minimums, or how should we think about the relationship between the two services? Yeah. Okay. That's right. Got it. Just in terms of the ratio of short-term advanced services backlog to revenue guidance, we should think of that as a subscription baseline upon which subscription revenue and then transactional revenue kind of layers. Yeah, exactly. Then you layer on the short term advanced services backlog on top of that, and to a really small extent, new implementations that are going live throughout the year. Those are the layers. Got it. Yeah. Can you guys clarify what was advanced services bookings in 2022? Just I think someone may have asked this earlier, but it seems like the growth rate expectation for advanced services might have moderated a little bit. I'm just curious kind of what is driving that moderation from what was, like, a 30-ish% CAGR to about 10. Thanks. Yeah. we haven't broken out the bookings delineation for 2022 between advanced services and non-advanced services. Our growth rate of 2023 is roughly similar, we expect. The 10% is revenue for advanced services. The way to think about it is really starting with bookings, of course, gets into ARR, AR, and then you get the revenue, right? bookings is substantially higher than the 10% we have in the guide for advanced services, recurring revenue year-over-year increase. Right. My understanding was that just advanced services revenue was going to grow at something like a 20%-30% CAGR through 2025. I'm just interested to know, like, has that expectation changed? If so, what is driving the changed expectation? That's it for me. Thank you, guys. Yeah. Okay. That, that, you know, that second part, the last part of your question, we really look at the business from a lens, you know, where point of care is down from a bookings perspective and a revenue perspective. The delta with the advanced services revenue, there's a, there's a large delta there, right? Because that is growing, right? And I think it's fair enough to say that the expectations are slightly lower for the time being, also given the current macroeconomic environment, but they are growing nicely. Again, we're somewhat, you know, conservative in our approach for planning for the year for 2023 as well. Those are things we take into consideration. Our next question comes from Bill Sutherland from The Benchmark Company. Please proceed. Hello, everybody. Peter, I'm not gonna say goodbye yet. We'll get around to that. Talked, I think, on a recent conference about improving the forecasting capabilities. I'm curious kind of what steps you've taken. Bill, you kind of broke up there a little bit. Could you repeat that? I'm sorry. That's okay. Mobile phones. I was just curious about what kind of things you've done to, you know, just further improve the forecasting and planning functions that you guys, I think, alluded to was something you want to focus on? Sorry, Bill. Can you repeat it again? We couldn't hear you. All right. You know, I don't want to hold up the call. Am I still fading in and out? Yeah. We missed the exact point of improving. Was it cash? Well, we couldn't quite hear the question. No, I was. Okay. You know what? I'll just get on my call back. I'll take care of that. Thank you. Yeah. Back to you, Bill. Our next question comes from David Larsen from BTIG. Please proceed. Hi. Can you give an update on how far along your base is with regards to the XT upgrades? Are you 60% of the way through, 70% of the way through? Just broadly speaking, like, over what time period does that entire upgrade process happen? Is it, like, a 10-year process and you're in year six, which means that over the next three years, the rest of your base is gonna have to upgrade to the XT? Do people have to upgrade to the XT, or can they choose not to? Yeah. Thanks. Yeah. Thank you, David, for the question. A couple of questions in your one question there. Yeah, we're above 60% of the upgrade cycle for XT specifically. Barbara, I think, Scott earlier indicated that there are more growth drivers than only the upgrade cycle. We also have expansion and competitive conversions as well. After 10 years, we do not provide technical services anymore. It means no more software upgrades and no break, fix, maintenance support either. For customers to stay in compliance, they generally upgrade the prior generation equipment. Okay. What I think I just heard was about 40% of your base still needs to upgrade to the XT, and that was gonna have to happen at some point over the next three years? Correct. I think what we said is we're above 60% now. It's a little less than 40%. Okay, great. For semiconductors, is pricing locked in for all of your semiconductor needs for 2023, and what about 2024? Like, if things heat up in Taiwan, between China and Taiwan, are you protected from that type of an event in terms of your COGS? Thanks. Yeah, I think, Dave. What we pointed out in the prepared remarks that we have $80 million of pre-receipts of semiconductors and sensors, so that gets us a good way into the year to fulfill customer demands. Then we have locked in pricing for the remainder of the year as well. You know, I would say we're not, from a risk factor perspective, we're not excluded from any geopolitical impact. You know, if that risk goes up, we'll continue to manage it as actively as we can. Okay. just in terms of, like, the hospital clients, I guess, Scott, what are you seeing on the ground? Is there enough labor available in terms of nurses and technicians to actually deploy these cabinets? Or is labor so tight people just aren't available to deploy these things? Thanks, Dave. Look, I mean, hospitals are still struggling with labor challenges. I think labor expenses continue to be higher than they were back in 2021, 2022, but it seems to be getting better. I think hospitals, like any other business or any other organization, just takes a bit of time to figure out the new operating reality, and that's certainly what it feels like. We are not seeing, at this point, you know, sort of major pushback on implementation, timing, et cetera, as a result of those labor constraints. Like we said, I think the environment's stabilized, our processes have stabilized, we know what's working, what's not working, which is the basis of our forecast or guidance in 2023. Okay. Then it's my understanding that there were some very favorable rulings by the Supreme Court and other courts that are positive for, like, the entire 340B program. Hospitals should be getting a pretty significant windfall from those rulings. Any sense for if and/or when that might happen? I would think that that could drive some demand for your solutions. I think there's a lot of activity in the courts regarding 340B, some good, some bad. I think that it continues to favor our Specialty Pharmacy Services and our 340B TPA business, we're taking a cautious outlook this year on and expect it relatively to be flat year-over-year. Okay. Just the last one, I'll hop back in the queue. In terms of your reported backlog, were there any changes in the way that backlog was estimated or was any backlog just kinda written off and reversed out that might reduce, like, the ending backlog for 2022 or your expected backlog for 2023? Were there any changes in, like, the way the calculations were being done? Thanks, Dave, for the question. The methodology hasn't changed for 2021 and 2022. We have forecasted 2023 ending backlog, which you can calculate it with the numbers that we provided today. Okay. Appreciate it. Thanks very much. Yep, I'll hop back in the queue. Thank you. Thanks, Dave. Our next question comes from the line of Stephanie Davis from SVB Securities. Please proceed. Hey, guys. Thank you for taking my questions from theater. I'm sorry to say I'm walking into the party just as you're leaving the party. It's like, you must be going to something much cooler than I am. I was a bit surprised by the quarter and the outlook reflecting better than expected product revenues, while service revenues was a little bit light. Was that more a function of just our mismodeling after last quarter's cuts, or is there anything to call out there in some of the shifting demand changes versus what you were seeing last print? Yeah. Particularly for the fourth quarter, it was a solid execution by the teams, if you will. Service came in a little bit light, overall executed well, plus the cost management came in well also for the year. On the guidance is just kind of the same sort of thing? Well, for the guide for the first quarter, right, you know, revenue is expected to be lower quarter-over-quarter, if you will, sequentially. That's the largest impact, if you will. Of course, the cost action will start kicking in more in the second quarter. Those are the dynamics if you model out the year quarter by quarter through 2023. Understood. Randy, are you still seeing predominantly or within CapEx budgets really contained to the larger health systems like you mentioned last quarter? Have we seen an extension of this, a little bit downstream to, like, a broader set of the customer base? I know last quarter you also mentioned that the budget changes tend to be more U-shaped. Is that kind of recovery arc playing out so far? Well, I think as Scott said that, you know, I think particularly after Q3, during Q3, a lot of these big health systems realized that the cost dynamics without the CARES Act money meant they had to stop their capital spend. I think they've now seen that adjustment, and they each quarter as we move forward, they're making adjustments to lower and improve their margins. In fact, I think last month or the last month, Kaufman reported some improvement in the margins. My guess is that'll continue to happen as we move forward. It's gonna take. These are slow-moving tankers. It takes them a little bit of a while. It feels like unless we hit some big macroeconomic another event that, you know, they're starting to slowly, you know, move forward and create more margin and put more investment into their institutions, which they need, which they know they need to make, particularly on pharmacy. All right. I'll hold. Thanks, folks. Our final question comes from the line of Allen Lutz from Bank of America. Please proceed. Thanks for taking the questions. I guess one for Peter and Scott. If we just look quarter-over-quarter, both revenue segments are down sequentially. I guess how should we think about the trough quarter? Is it reasonable to think that 1Q is the trough quarter in terms of revenue for both of these segments? Or is it something that's going to be more of a hockey stick ramp over the course of the year? Just trying to understand line of sight into the guide and what you're seeing to give you confidence in the inflection over the course of the year. Thanks. Yeah. Thanks, Allen. Good question. Yeah, of course, for the fourth quarter through the first quarter, there's always a little bit of seasonality. So you gotta take that into account. Then we see product revenue modestly increasing through the year, mostly based on already contracted backlog that we talked about in the prepared remarks. Then the asset services revenue and service revenue in totality is entirely the vast majority of that is really based on the backlog of plant implementations. Right. That's how we modeled it out. You can do the same. Yeah. Got it. Thank you very much. Thanks, Allen. I would now like to turn the call over to Randall Lipps for closing remarks. Well, thank you everyone for joining the call. Before I conclude the call, I wanted to give a shout-out to the global Omnicell team for their hard work and resilience. I mean, throughout 2022, they did not waver on delivering exceptional service to our customers, pursuing our transformational journey to an as a service business. It is a hard work and, particularly supporting each other and the communities we serve. On behalf of myself and the board of directors and executive leadership team, I thank all of you, dear employees, for the great work of 2022. We look forward to 2023 as we get back to that growth mode and get forward at to transforming the pharmacy. Thanks, everyone. Thank you, everyone. Thank you, ladies and gentlemen. This does conclude today's call. Thank you for your participation. You may now disconnect.